NYSE:PBHPrestige Consumer Healthcare Stock Price, Forecast & News

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PBH shares have increased by 6.0% and is now trading at $38.08.
View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Prestige Consumer Healthcare.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Prestige Consumer Healthcare Inc (NYSE:PBH) announced its quarterly earnings data on Thursday, May, 7th. The company reported $0.82 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.74 by $0.08. The firm had revenue of $251.20 million for the quarter, compared to analysts' expectations of $239.65 million. Prestige Consumer Healthcare had a net margin of 14.77% and a return on equity of 13.33%. Prestige Consumer Healthcare's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.72 EPS.
View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare updated its first quarter earnings guidance on Thursday, May, 7th. The company provided EPS guidance of $0.70 or more for the period, compared to the Thomson Reuters consensus EPS estimate of $0.69. The company issued revenue guidance of ~$220 million or more, compared to the consensus revenue estimate of $232.21 million.

7 equities research analysts have issued twelve-month price objectives for Prestige Consumer Healthcare's shares. Their forecasts range from $43.00 to $97.00. On average, they anticipate Prestige Consumer Healthcare's share price to reach $69.33 in the next twelve months. This suggests a possible upside of 82.1% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare.

News stories about PBH stock have been trending negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Prestige Consumer Healthcare.

Prestige Consumer Healthcare saw a increase in short interest in July. As of July 15th, there was short interest totaling 5,670,000 shares, an increase of 5.8% from the June 30th total of 5,360,000 shares. Based on an average trading volume of 459,500 shares, the days-to-cover ratio is currently 12.3 days. Approximately 11.4% of the company's stock are short sold.
View Prestige Consumer Healthcare's Current Options Chain.

Some companies that are related to Prestige Consumer Healthcare include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), USANA Health Sciences (USNA), Inter Parfums (IPAR), Revlon (REV), Nature's Sunshine Products (NATR) and Veru (VERU).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Johnson & Johnson (JNJ), TG Therapeutics (TGTX), Flexion Therapeutics (FLXN), Marathon Petroleum (MPC), Pfizer (PFE), AT&T (T) and Thermo Fisher Scientific (TMO).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a variety of retail and institutional investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (0.60%), Wedge Capital Management L L P NC (0.55%), North Star Asset Management Inc. (0.52%), Peregrine Capital Management LLC (0.30%), UBS Group AG (0.27%) and NN Investment Partners Holdings N.V. (0.22%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett, Ronald M Lombardi and Timothy Connors.
View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., Dalton Greiner Hartman Maher & Co., Skyline Asset Management LP, Dupont Capital Management Corp, Denali Advisors LLC, North Star Asset Management Inc., and Vident Investment Advisory LLC.
View insider buying and selling activity for Prestige Consumer Healthcare.

PBH stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, First Trust Advisors LP, Duality Advisers LP, Mackay Shields LLC, Lapides Asset Management LLC, Nisa Investment Advisors LLC, Wedge Capital Management L L P NC, and Wakefield Asset Management LLLP.
View insider buying and selling activity for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $38.08.

Prestige Consumer Healthcare has a market capitalization of $1.91 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]